Cipla Ltd Q3 FY2025 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/eh3bi1b68fuwt0kellw8hthy.pdf

Key Takeaways


US Business: Supply Fixes and Pipeline Inflection

Vohra: "the last three years we have now been setting up facilities in the US. So, there will come a time when we begin to understand the economics of shipping straight from India and having potential duties or whatever and the freight with it, linking up with what the cost of manufacturing and supplying from the US is. So, in some ways our model is derisked to a large extent for our portfolio"

Pipeline: The Step-Function Shift

Vohra: "if your question is whether this will double, triple, it's going to be moving up step functions, it's not going to be moving marginal increases with each asset being approved."

India Business: Investing Margin Gains into Growth


International Markets: South Africa and EMEU Deliver


Quality and Facilities: Clearing the Overhang

Vohra: "quality is a function of practice equipment and talent. And we have worked on all three of them."

Margins: The 28% Print and Why It Will Not Repeat

Adukia: "No, I don't think Cipla can do 28% EBITDA margins... 28% is not a sustainable margin for us. That's what I meant."

Guidance & Commitments

CommitmentSpecificsTimeline
FY26 revenue growthRetain guidance to grow top lineFY26
Generic Advair launchLaunch from US facilityLate H1 FY26
Generic Abraxane launchLaunch from Goa facility post-approval; 6–9 months from approval dateBack end of H2 FY26
Lanreotide supply normalizationFull capacity from partner; ramp-up and inventory buildEnd of March (Q4), ramp in Q1
Lanreotide capacity expansion20–25% higher than index level of 100; also examining alternate sitesPost-April
Peptide launchesTwo launchesFY26
Three sizable US respiratory assetsLaunch in the USNext 15–18 months
Symbicort launchSite transfer done; approval and launchH2 FY27
R&D spend5–6% of revenueOngoing
EBITDA margin guidanceTo be provided once budget is finalizedFY26

Key Metrics

MetricQ3 FY25
Revenue₹7,073 cr, +8% YoY
EBITDA margin28%, up 184 bps YoY and 138 bps QoQ; not sustainable at this level
Gross margin after material cost68%, 166 bps above last year
Profit after tax₹1,571 cr, ~22% of sales
Effective tax rate25.5%, adjusted for one-offs; full-year guidance 27%–28%
R&D investment₹360 cr, ~5% of revenue; FY25 guidance retained at 5%–6%
Total expenses₹2,820 cr, in line with revenue growth
Net cash equivalent~₹8,947 cr, as of 31st Dec 2024; debt including lease liability at ₹466 cr
ROIC30%
North America quarterly revenue$226 million
One India revenue growth+10% YoY
One Africa revenue growth+9% YoY in USD terms; South Africa +21% in ZAR terms
EMEU revenue growth+20% YoY in USD terms
Albuterol market share21%, as per IQVIA MAT week ended 27th Dec 2024; slightly ahead recently
Chronic mix61.5%, as per MAT IQVIA December '24
Brands with revenue >₹100 cr in IPM26, five added during the quarter
India volume growth~2%, balance from price and new introductions
Price erosion in US base portfolioHigh single digit on an overall basis
Lanreotide supply level40%–50% of partner's full capacity index; expected back to 100 by end of March
US respiratory portfolio annual run-rateSlightly more than $150–$200 million
Consumer wellness India quarterly run-rate~₹380 cr, up from ~₹250 cr per quarter last year
Field force additions (India branded Rx)1,800+ feet on ground added from FY23 to 9M FY25
Trade generics retail task force500+ feet on ground added
PEPFAR exposureLess than ₹0.1 cr, less than 0.2% of Cipla's business
FY25 EBITDA guidanceTrending higher than 24.5%–25.5% earlier range
Dividend payout guidance~30%
Symbicort US approval timelineWithin 18 months, second-half FY27 launch
Generic Advair launch timelineLate H1 FY26
Generic Abraxane launch timelineBack end of H2 FY26, post-approval